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SUMMARY 
Hepatitis E viral infection has been reported in North Africa, Western Africa and 
some outbreaks in refugee camps in Somalia and Sudan. We present the rare case of 
a Kenyan health care worker with documented acute viral Hepatitis E infection. 
INTRODUCTION 
The Hepatitis E virus was discovered in the early 
1980’s by scientists who were testing the stored blood 
samples drawn from patients during an acute hepatitis 
epidemic which swept through New Delhi, India 
in 1955. It was originally designated as an Enteric 
non-A-non-B. Hepatitis virus and was later renamed 
Hepatitis E due to its enteric nature but also because 
made alphabetical sense because Hepatitis viruses A 
to D had been discovered up until then (1). We believe 
this is the first documented case of acute viral Hepatitis 
E injection in Kenya. 
CASE REPORT
The patient is a 43 year old African male who presented 
to our hospital with a nine day history of nausea, 
vomiting and generalised pruritus. He is a nurse and 
had been working in Sudan at a refugee camp run by a 
non-governmental organisation. 
 The symptoms started nine days prior to his 
presentation and he had been started on Ciprofloxacin 
based on a positive widal test for Salmonella Typhi. Two 
malaria slides done. There reported negative. There was 
no improvement in symptoms after three days of taking 
Ciprofloxacin so he travelled to Kenya for treatment. 
 He presented to our casualty with complaints of 
persistent nausea and vomiting. The vomiting was 
non-projectile, bilious and sometimes blood stained. He 
denied any abdominal pain or diarrhoea. He also had 
generalised pruritus with no associated rash and on further 
enquiry he reported pale stools and deeply yellow urine. 
 His past medical history was significant for 
admission five years prior with a diagnosis of Acute 
Stress Reaction. On a routine outpatient visit six months 
prior to the current presentation, his liver function tests 
were normal. He repurted being allergic to Sulphur drugs. 
He was married with three children and did not smoke 
or take any alcohol. He reported no family history 
of liver disease or malignancy and no use of herbal 
preparations. 
 On examination we found a young man with 
normal vital signs. Scleral jaundice was noted but he had 
no stigmata of chronic liver disease and no hepatic flap. 
He was mildly tender in the right upper quadrant with 
a negative Murphy’s sign. Liver span was 10 centimetre. 
The rest of the systemic examination was normal. 
 His initial investigations showed clevated liver 
enzymes with negative screens for Hepatitis A, B and 
C. However  Hepatitis E IgM and IgG antibodies were 
found to be positive. Haemogram, Renal function tests, 
Amylase, Lipase, CA 19-9, Ferritin and Ceruloplasmin 
levels were normal. HIV Elisa was negative. 
 A hepatobiliary ultrasound revealed a normal liver 
with a thickened gall bladder but no gall stones and 
no pericholecystic fluid and this was confirmed on a 
computed tomography scan or the abdomen. 
Test Normal Values 5th Jan 2010 7th Jan 2010 21st Jan 2010
Total Bilirubin 0-2lumol/l 364 286 52
Direct bilirubin 0-3.4umol/l 185 148 19
SGOT 30.5U/L 257 1,800 38
SGPT 10.8U/L 137 2,450 80
ALP 72U/L 206 163 92
Gramma GT 29U/L 81  81  42
Serum Protein 82.7U/L 66
Serum Albumin 47.0U/L 34
He was started on supportive management with 
intravenous fluids and multivitamin supplements 
and was allowed home after four days. 
 Two weeks later, his repeat liver function tests were 
markedly improved. He reported complete resolution 
symptoms and was able to report back to work. 
DISCUSSION 
The Hepatitis E virus is a single stranded RNA virus 
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with an icosahedral structure which belongs to the 
genus Hepevirus and family Hepeviridae. The HEV 
genome contains three open reading frames (ORFs). 
ORF-1 codes for the non-structural proteins responsible 
for final replication. ORF-2 contains genes encoding 
the capsid. The function of ORF-3 is not very clear, but 
antibodies directed against ORF-3 epitopes have been 
identified (1). 
 There are four documented genotypes of Hepatitis 
E virus with different geographical distribution and 
differing levels of virulence. Genotype 2 includes isolates 
from Asia, the Middle East and North Africa. Genotype 2 
has been found in Mexico and Nigeria. Genotype 3  was 
recovered from swine in North America, Europe, Egypt, 
Asia and New Iceland and from humans in North and 
South America, Europe, Japan and China. Genotype 4 
was found in humans and swine in Asia. Genotype 1 
is the most virulent which may explain the severity of 
disease in India where it is the most common subtype 
found whereas genotypes 3 and 4 are less pathogenic 
and may explain subclinical disease seen in the North 
America and Europe. 
 Hepatitis E is endemic to Asia, Africa, Central 
Amcrica and the Middle East. There have been some 
sporadic outbreaks in other parts of the world with the 
largest outbreak occurring in China between 1986 and 
1988 where more than 100,000 cases were documented. 
Outbreaks have also been reported in refugee camps in 
Somalia and Sudan. It occurs mainly in young adults 
aged between 15 to 40years and is usually subclinical 
when it occurs in children. Severe hepatitis can occur 
in adults and mortality is between 1 to 2 %. 
 Transmission is mainly by faecal-oral route 
following contamination of sources of drinking water. 
Zoonotic transmission from animal reservoirs has been 
suggested by the presence of high levels of anti-HEV 
antibodies in people in close contact with animals like 
veterinarians and farmers. Rodents have also been 
suggested as reservoirs causing zoonotic transmission 
(2). 
 Parenteral transmission by transfusion 
of blood and blood products also occurs and 
mother to child transmission has also been 
documented. However there is no evidence of 
transmission via breast milk. 
 Person to person spread of Hepatitis E has not been 
documented clearly in the past but a recent study carried 
out during an outbreak in Uganda suggests that person 
to person transmission was occurring among household 
members(3). 
 Once the contaminated water is ingested the 
incubation period lasts between three to nine weeks 
during which time the virus replicates mainly in the 
liver. There is a prodromal phase during which the 
patient experiences myalgia, arthralgia, low grade fevers, 
anorexia, nausea and vomiting. This is followed by the 
icteric phase characterised by symptoms of acute viral 
hepatitis. These include jaundice, pruritus, dark urine 
and palecoloured stools. The main findings on physical 
exam are jaundice and sometimes hepatomegaly. 
Subclinical disease with no symptoms occurs mainly 
in children. 
 Liver transaminases and bilirubin levels are elevated 
and they usually resolve along with the clinical symptoms 
in about eight weeks. Coagulopathy is rare except in cases 
of liver failure but there have been three documented 
cases of thrombocytopenia associated with Hepatitis 
E infection (4). The exact mechanism was unclear but 
the process was thought to be immune mediated. 
 Hepatitis E does not run a chronic course and 
similar to Hepatitis A presence of antibodies seems to 
confer immunity from re-infection. 
Liver histology shows a cholestatic picture with stasis of 
canalicular bile and marked proliferation of intrlobular 
bile ductules and inflammatory infiltrate of mononuclear 
cells. 
 Pregnant women have more severe hepatitis 
usually leading to fulminant liver failure with high 
mortality rates of 15-25%.This is thought to be due to 
the presence of high level of steroid hormones that cause 
immunosuppression thus promoting viral replication 
and also inhibit liver regeneration by inactivation of 
Nuclear Factor kappa B (NF-kB) which plays a major 
role in both immunity and liver regeneration (5). 
 Diagnosis of Hepatitis E virus is based on detection 
of anti-Hepatitis E Viral Antibodies in blood as well as 
detection of Hepatitis E RNA copies in serum, liver, 
and stool samples in the early stages of infection. 
Immunoglobulin M is present in early infection and 
remains detectable for up to six months. Immunoglobulin 
G is also detectable from the second week of infection and 
both can remain positive for more than six months. 
 Hepatitis E Viral RNA copies become undetectable 
between one to six weeks from symptom onset. 
Management of Hepatitis E is mainly supportive since 
the disease is self-limiting in most cases. In severe cases 
with fulminant liver failure, liver transplantation is 
required. Good sanitation and complete separation of 
sewage from water sources to prevent contamination 
can prevent transmission of Hepatitis E  vaccine to 
prevent infection with Hepatitis E is currently being 
developed and has shown promising results (6). 
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